Propensity matched analysis of single access technique for Impella-assisted unprotected left main percutaneous coronary intervention.

IF 1.6 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
Raef Ali Fadel, Benjamin Hofeld, Herbert D Aronow, Ahmad Jabri, Pedro Engel, Gerald Koenig, Muhammad Memon, Mohammad Alqarqaz, Khaldoon Alaswad, Brittany Fuller, Asaad Nakhle, Vikas Aggarwal, Brian O'Neill, Tiberio Frisoli, Mir Babar Basir, Henry Kim, William O'Neill, Pedro Villablanca
{"title":"Propensity matched analysis of single access technique for Impella-assisted unprotected left main percutaneous coronary intervention.","authors":"Raef Ali Fadel, Benjamin Hofeld, Herbert D Aronow, Ahmad Jabri, Pedro Engel, Gerald Koenig, Muhammad Memon, Mohammad Alqarqaz, Khaldoon Alaswad, Brittany Fuller, Asaad Nakhle, Vikas Aggarwal, Brian O'Neill, Tiberio Frisoli, Mir Babar Basir, Henry Kim, William O'Neill, Pedro Villablanca","doi":"10.1016/j.carrev.2025.05.024","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The single access for high-risk percutaneous coronary intervention (SHiPCI) technique is an intriguing alternative to traditional dual access Impella-assisted PCI, potentially reducing access-site complications. Current data is limited to retrospective case studies.</p><p><strong>Objectives: </strong>To analyze procedural complications and clinical outcomes of SHiPCI.</p><p><strong>Methods: </strong>This single-center retrospective observational study evaluated consecutively admitted patients undergoing high-risk unprotected left main PCI (UPLM-PCI) from 2018 through 2023. Patients were grouped according to index strategy of single or dual access Impella-assisted UPLM-PCI, and propensity score matching without replacement was used to match patients 1:1. The primary outcome was a composite of all-cause in-hospital mortality, major bleeding, vascular access site complications, and blood transfusion.</p><p><strong>Results: </strong>Six-hundred patients underwent UPLM-PCI during the study period, and one hundred patients were matched (50 patients per group). There were no significant differences in baseline characteristics between the two groups. Up-front balloon tamponade assistance was higher in the dual access group (14 % vs 4.0 %, p = 0.027), and rate of successful hemostasis post-closure was lower (82 % vs 100 %, p = 0.001). The primary composite outcome occurred in 7 patients (14 %) in the single access group, compared to 16 patients (32 %) in the dual access group (p = 0.033). Patients in the dual-access group had higher rates of major bleeding (17 % vs 2 %, p = 0.014).</p><p><strong>Conclusions: </strong>SHiPCI compared to standard dual access for Impella-assisted UPLM-PCI demonstrated a lower rate lower rate of the composite outcome, driven primarily by a lower rate of major bleeding. Prospective randomized controlled trials are needed to delineate the efficacy and safety of SHiPCI.</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Revascularization Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.carrev.2025.05.024","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The single access for high-risk percutaneous coronary intervention (SHiPCI) technique is an intriguing alternative to traditional dual access Impella-assisted PCI, potentially reducing access-site complications. Current data is limited to retrospective case studies.

Objectives: To analyze procedural complications and clinical outcomes of SHiPCI.

Methods: This single-center retrospective observational study evaluated consecutively admitted patients undergoing high-risk unprotected left main PCI (UPLM-PCI) from 2018 through 2023. Patients were grouped according to index strategy of single or dual access Impella-assisted UPLM-PCI, and propensity score matching without replacement was used to match patients 1:1. The primary outcome was a composite of all-cause in-hospital mortality, major bleeding, vascular access site complications, and blood transfusion.

Results: Six-hundred patients underwent UPLM-PCI during the study period, and one hundred patients were matched (50 patients per group). There were no significant differences in baseline characteristics between the two groups. Up-front balloon tamponade assistance was higher in the dual access group (14 % vs 4.0 %, p = 0.027), and rate of successful hemostasis post-closure was lower (82 % vs 100 %, p = 0.001). The primary composite outcome occurred in 7 patients (14 %) in the single access group, compared to 16 patients (32 %) in the dual access group (p = 0.033). Patients in the dual-access group had higher rates of major bleeding (17 % vs 2 %, p = 0.014).

Conclusions: SHiPCI compared to standard dual access for Impella-assisted UPLM-PCI demonstrated a lower rate lower rate of the composite outcome, driven primarily by a lower rate of major bleeding. Prospective randomized controlled trials are needed to delineate the efficacy and safety of SHiPCI.

单通道技术在impella辅助下无保护左主干经皮冠状动脉介入治疗中的倾向匹配分析。
背景:单通道高风险经皮冠状动脉介入治疗(SHiPCI)技术是传统双通道impella辅助PCI的一个有趣的替代方案,潜在地减少了通道部位的并发症。目前的数据仅限于回顾性的案例研究。目的:分析SHiPCI的手术并发症及临床结果。方法:本单中心回顾性观察性研究对2018年至2023年接受高危无保护左主干PCI (UPLM-PCI)的患者进行连续评估。根据单路或双路impela辅助UPLM-PCI的指标策略对患者进行分组,采用倾向评分匹配无置换,1:1匹配患者。主要结局是全因住院死亡率、大出血、血管通路并发症和输血的综合结果。结果:600例患者在研究期间行UPLM-PCI,匹配100例患者(每组50例)。两组患者的基线特征无显著差异。双通道组正面球囊填塞辅助率较高(14%比4.0%,p = 0.027),闭合后成功止血率较低(82%比100%,p = 0.001)。单通道组有7例(14%)患者出现主要复合结局,双通道组有16例(32%)患者出现主要复合结局(p = 0.033)。双通道组患者大出血发生率较高(17% vs 2%, p = 0.014)。结论:SHiPCI与标准双通道impella辅助UPLM-PCI相比,复合结果的发生率更低,主要是由于大出血发生率更低。需要前瞻性随机对照试验来描述SHiPCI的有效性和安全性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cardiovascular Revascularization Medicine
Cardiovascular Revascularization Medicine CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
3.30
自引率
5.90%
发文量
687
审稿时长
36 days
期刊介绍: Cardiovascular Revascularization Medicine (CRM) is an international and multidisciplinary journal that publishes original laboratory and clinical investigations related to revascularization therapies in cardiovascular medicine. Cardiovascular Revascularization Medicine publishes articles related to preclinical work and molecular interventions, including angiogenesis, cell therapy, pharmacological interventions, restenosis management, and prevention, including experiments conducted in human subjects, in laboratory animals, and in vitro. Specific areas of interest include percutaneous angioplasty in coronary and peripheral arteries, intervention in structural heart disease, cardiovascular surgery, etc.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信